

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



華潤醫藥集團有限公司

China Resources Pharmaceutical Group Limited

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3320)

ANNOUNCEMENT

PRINCIPAL FINANCIAL INFORMATION OF CR SANJIU FOR THE YEAR ENDED 31 DECEMBER 2023

On 22 March 2024, CR Sanjiu released its annual report for the year ended 31 December 2023.

China Resources Sanjiu Medical & Pharmaceutical Company Limited (華潤三九醫藥股份有限公司) (“**CR Sanjiu**”) is a company incorporated in the People’s Republic of China. The shares of CR Sanjiu are listed on the Shenzhen Stock Exchange. As of the date of this announcement, CR Sanjiu is indirectly owned as to 63.00% by China Resources Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) and is a subsidiary of the Company.

On 22 March 2024, CR Sanjiu released its annual report for the year ended 31 December 2023 (the “**CR Sanjiu Audited Annual Financials**”). Set out below are the key financial information of the CR Sanjiu Audited Annual Financials:

	As of 31 December 2023 <i>(RMB)</i> <i>(audited)</i>	As of 31 December 2022 <i>(RMB)</i> <i>(audited)</i>	Increase <i>(%)</i>
Total assets	40,148,455,933.08	27,122,781,699.16	48.02%
Net assets attributable to shareholders of the listed company	18,967,141,875.14	17,009,633,485.53	11.51%
	For the year ended 31 December 2023 <i>(RMB)</i> <i>(audited)</i>	2022 <i>(RMB)</i> <i>(audited)</i>	Increase <i>(%)</i>
Revenue	24,738,963,319.76	18,079,461,482.75	36.83%
Net profit attributable to the shareholders of the listed company	2,852,931,664.85	2,448,802,103.34	16.50%
Net profit attributable to the shareholders of the listed company (excluding extraordinary gains or losses)	2,710,984,203.99	2,218,917,217.36	22.18%
Net cash flow from operating activities	4,191,742,949.80	3,006,375,016.25	39.43%
Basic earnings per share <i>(RMB/share)</i>	2.90	2.48	16.94%
Diluted earnings per share <i>(RMB/share)</i>	2.90	2.48	16.94%
Weighted average return on net asset <i>(%)</i>	15.86%	15.15%	0.71 percentage points

As determined by the board of directors of CR Sanjiu, CR Sanjiu proposed to distribute a cash dividend of RMB15 (inclusive of tax) for every 10 shares to all shareholders of CR Sanjiu based on the total share capital of CR Sanjiu on the date of equity distribution registration, using the capital reserve fund, every 10 shares of CR Sanjiu shareholders will be increased by 3 shares. Before the equity distribution registration date, if there is any change in the total number of shares eligible for profit distribution rights, the total number of shares eligible for profit distribution rights on the registration date of the equity distribution scheme shall be used as the base, and the total distribution amount shall be adjusted according to the principle of unchanged distribution ratio. Such proposal shall be submitted for shareholders’ approval at CR Sanjiu’s 2023 annual general meeting.

The CR Sanjiu Audited Annual Financials have been prepared and audited in accordance with the PRC Generally Accepted Accounting Principles. The financial information is limited to CR Sanjiu only and does not represent or provide a complete view of the operational or financial status of the Group. **Shareholders and potential investors should exercise caution when dealing in securities of the Company and should not rely solely on such information.**

For further details of the CR Sanjiu Audited Annual Financials, please refer to the annual report for the year ended 31 December 2023 published by CR Sanjiu on the website of the Shenzhen Stock Exchange (www.szse.cn).

By order of the Board of Directors
China Resources Pharmaceutical Group Limited
Han Yuewei
Chairman

Shenzhen, 25 March 2024

As at the date of this announcement, the Board comprises Mr. Han Yuewei as chairman and non-executive Director, Mr. Bai Xiaosong, Mr. Tao Ran and Mdm. Deng Rong as executive Directors, Mdm. Guo Wei, Mr. Sun Yongqiang, Mr. Hou Bo and Mdm. Jiao Ruifang as non-executive Directors and Mdm. Shing Mo Han Yvonne, Mr. Kwok Kin Fun, Mr. Fu Tingmei and Mr. Zhang Kejian as independent non-executive Directors.